Anti-Vascular Endothelial Growth Factor Therapeutics Market Share, Size, Trends, Industry Analysis Report, By Product (Eylea, Lucentis, Beovu); By Disease (Macular Edema, Diabetic Retinopathy, Retinal Vein Occlusion, Age-related Macular Degeneration); By

Anti-Vascular Endothelial Growth Factor Therapeutics Market Share, Size, Trends, Industry Analysis Report, By Product (Eylea, Lucentis, Beovu); By Disease (Macular Edema, Diabetic Retinopathy, Retinal Vein Occlusion, Age-related Macular Degeneration); By Region; Segment Forecast, 2022 - 2030

The global anti-vascular endothelial growth factor therapeutics market size is expected t-reach USD 13.32 billion by 2030, according t-a new study by Polaris Market Research. The report “Anti-Vascular Endothelial Growth Factor Therapeutics Market Share, Size, Trends, Industry Analysis Report, By Product (Eylea, Lucentis, Beovu); By Disease (Macular Edema, Diabetic Retinopathy, Retinal Vein Occlusion, Age-related Macular Degeneration); By Region; Segment Forecast, 2022 – 2030” gives a detailed insight int-current market dynamics and provides analysis on future market growth.

The anti-vascular endothelial development aspect therapeutics industry is growing due t-new product releases, FDA approvals, and research developments. For instance, in September 2021, Byooviz (ranibizumab-nuna) was approved by the US Food and Drug Administration as the first generic drug t-Lucentis (ranibizumab injection) for treating a variety of eye diseases and disorders, which include neovascular (wet) age-related macular degeneration (nAMD), a major cause of damage t-the optic nerve in Americans aged 65 and older.

Byooviz is als-approved for the treatment of macular edoema (fluid build-up) caused by retinal vein obstruction (retinal vein blockage) and myopic choroidal neovascularization, a vision-threatening consequence of myopia (nearsightedness). If approved, faricimab will be the foremost, and only bispecific antibody developed, especially for the eye.

Further, the rising pipeline drugs for the treatment of these diseases, such as AMD, is the aspect that is driving the anti-vascular endothelial development aspect of therapeutics industry development during the forecast period. ADVM-022 and OpRegen are in Phase I and I/II, correspondingly, in the AMD pipeline. Also, GB-102and KSI-301 are in Phase II, and II/III are in the development phase.

Besides, Amgen, Inc. is exploring its ABP 938, which is in the late stages of development (Phase III). Thus, the pipeline products launched by the major players for the treatment of AMD are the factor boosting the industry development during the forecast period. Based on the product, the eylea segment accounted for the leading share in the industry in 2021. Throughout the forecast period, the category is expected t-maintain its dominance due t-developments in formulations and sophisticated drug delivery technologies.

Market players such as Bausch Health Companies, Inc., Viatris, Inc., Amgen, Inc., Coherus Biosciences, Eli Lilly, F. Genentech Inc., Hoffmann-La Roche Ltd., Pfizer, Inc., and Xbrane Biopharma AB are some key players operating in the global anti-vascular endothelial growth factor therapeutics industry.

In July 2021, the US Food and Drug Administration (FDA) had approved Genentech’s Biologics License Application (BLA) for faricimab for the management of wet, or based on superficial, age-related macular degeneration (AMD) and diabetic macular edoema (DME) under Priority Review.

The FDA has als-approved the company’s diabetic retinopathy application. If agreed, faricimab will be the foremost and singular bispecific antibody explicitly created for the eye. Thus, the product launches and US FDA approvals for the drugs t-treat various diseases are the factors boosting the market growth during the forecast period.

Polaris Market Research has segmented the anti-vascular endothelial growth factor therapeutics market report based on product, disease, and region:

Anti-Vascular Endothelial Growth Factor Therapeutics, Product Outlook (Revenue – USD Million, 2018 – 2030)

• Eylea
• Lucentis
• Beovu

Anti-Vascular Endothelial Growth Factor Therapeutics, Disease Outlook (Revenue – USD Million, 2018 – 2030)

• Macular Edema
• Diabetic Retinopathy
• Retinal Vein Occlusion
• Age-related Macular Degeneration

Anti-Vascular Endothelial Growth Factor Therapeutics, Regional Outlook (Revenue – USD Million, 2018 – 2030)

• North America
• U.S.
• Canada
• Europe
• France
• Germany
• UK
• Italy
• Netherlands
• Spain
• Austria
• Asia Pacific
• China
• India
• Japan
• Malaysia
• South Korea
• Indonesia
• Latin America
• Mexico
• Brazil
• Argentina
• Middle East & Africa
• UAE
• Saudi Arabia
• Israel
• South Africa